Drug Trial Radar · NCT03816345
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 16, 2019
Primary completion
Mar 30, 2028
Study completion Mar 30, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jan 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and/or effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.
Conditions
- Autoimmune Disease
- Crohn Disease
- Dermatomyositis
- Hematopoietic and Lymphoid Cell Neoplasm
- Inflammatory Bowel Disease
- Malignant Solid Neoplasm
- Multiple Sclerosis
- Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Sjogren Syndrome
- Systemic Lupus Erythematosus
- Systemic Scleroderma
- Ulcerative Colitis
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood, CSF, tissue, stool and urine samples
CabozantinibDrug
Given PO
FluoropyrimidineDrug
Given fluoropyrimidine
IpilimumabBiological
Given IV
NivolumabBiological
Given IV
Platinum CompoundDrug
Given platinum containing chemotherapy
Platinum DoubletDrug
Given platinum doublet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 100 days after completion of study treatment
- Change in disease assessmentsTime frame: Baseline up to 100 days after completion of study treatment
- Overall response rateTime frame: Up to 5 years after completion of study treatment
- Changes in serum chemokines and circulating immune cells over timeTime frame: Baseline up to 100 days after completion of study treatment
- Gene expression in normal tissuesTime frame: Up to 100 days after completion of study treatment
- Clinical measures of interestTime frame: Up to 100 days after completion of study treatment
Locations
52 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Active not recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut · Recruiting
Yale University
New Haven, Connecticut · Recruiting
MedStar Georgetown University Hospital
Washington D.C., District of Columbia · Recruiting
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Active not recruiting
Northwestern University
Chicago, Illinois · Active not recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois · Active not recruiting
University of Kansas Clinical Research Center
Fairway, Kansas · Recruiting
HaysMed
Hays, Kansas · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
Lawrence Memorial Hospital
Lawrence, Kansas · Recruiting
The University of Kansas Cancer Center - Olathe
Olathe, Kansas · Recruiting
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas · Recruiting
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas · Recruiting
Mercy Hospital Pittsburg
Pittsburg, Kansas · Suspended
Salina Regional Health Center
Salina, Kansas · Recruiting
University of Kansas Health System Saint Francis Campus
Topeka, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky · Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland · Recruiting
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland · Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland · Active not recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan · Active not recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
University Health Truman Medical Center
Kansas City, Missouri · Recruiting
University of Kansas Cancer Center - North
Kansas City, Missouri · Recruiting
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri · Recruiting
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, Missouri · Suspended
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
Siteman Cancer Center at Christian Hospital
St Louis, Missouri · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York · Recruiting
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.